Condition (MeSH)
Urethral Neoplasms
ClinicalTrials.gov lists 95 trials for Urethral Neoplasms or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 19.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
95 of the 95 trials are tagged with Urethral Neoplasms itself; the rest are tagged with a narrower condition beneath it.
When did Urethral Neoplasms trials start? (30)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 8
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 2 |
| 2024 | 1 |
| 2023 | 2 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 4 |
| 2018 | 3 |
| 2017 | 7 |
| 2016 | 2 |
Showing 10 of 30 earlier years.
No forecast is made for this condition: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Urethral Neoplasms trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 21 |
| Phase 1/2 | 4 |
| Phase 2 | 53 |
| Phase 2/3 | 1 |
| Phase 3 | 8 |
| Not applicable | 4 |
| Observational | 4 |
How many Urethral Neoplasms trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 6 |
| Active, not recruiting | 14 |
| Completed | 62 |
| Terminated | 9 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Urethral Neoplasms trials? (7)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 19 |
| Eastern Cooperative Oncology Group | 6 |
| SWOG Cancer Research Network | 6 |
| European Organisation for Research and Treatment of Cancer - EORTC | 4 |
| Eli Lilly and Company | 3 |
Showing 5 of 7 sponsors.
Which drugs are being tested for Urethral Neoplasms? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| (nab)-paclitaxel | 10 |
| NIVOLUMAB | 6 |
| PEMBROLIZUMAB | 5 |
| Avelumab | 4 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Gemcitabine/Gemzar | 25 |
| Cisplatin 1 | 17 |
| or carboplatin | 10 |
| Doxorubicine | 6 |
| Docetetaxel | 6 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Urethral Neoplasms trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Fatigue | 159 | 13 |
| Hemoglobin decreased | 136 | 2 |
| Platelet count decreased | 95 | 4 |
| Creatinine increased | 77 | 4 |
| Neutrophil count decreased | 69 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Urethral Neoplasms? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| The accuracy of magnetic resonance imaging (MRI) in predicting the invasion of the tunica albuginea and the urethra during the primary staging of penile cancer. | BJU international | 2016 | Yes |
| Chemotherapy for penile and urethral carcinoma. | The Urologic clinics of North America | 2010 | Yes |
| Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. | Cancer | 2006 | Yes |
| Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. | BJU international | 2005 | Yes |
| Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. | Cancer | 1990 | Yes |
Showing 5 of 7 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.